FY2024 EPS Estimates for Bruker Decreased by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for Bruker in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $2.38 per share for the year, down from their previous estimate of $2.61. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2025 earnings at $0.70 EPS.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 24.92% and a net margin of 11.29%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter in the prior year, the business earned $0.74 earnings per share. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the company. Citigroup cut their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. TD Cowen lowered their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Wells Fargo & Company cut their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Barclays reduced their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Trading Up 2.6 %

NASDAQ:BRKR opened at $60.49 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a one year low of $54.55 and a one year high of $94.86. The company has a market cap of $9.16 billion, a PE ratio of 25.10, a PEG ratio of 2.32 and a beta of 1.20. The firm has a 50-day moving average of $63.83 and a 200-day moving average of $66.47.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norden Group LLC lifted its stake in Bruker by 41.8% in the first quarter. Norden Group LLC now owns 5,944 shares of the medical research company’s stock valued at $558,000 after purchasing an additional 1,753 shares during the last quarter. Larson Financial Group LLC bought a new position in shares of Bruker during the 1st quarter worth $178,000. Texas Permanent School Fund Corp increased its holdings in Bruker by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 81,161 shares of the medical research company’s stock worth $7,624,000 after acquiring an additional 1,050 shares during the last quarter. Duality Advisers LP raised its stake in Bruker by 12.5% in the 1st quarter. Duality Advisers LP now owns 8,619 shares of the medical research company’s stock valued at $810,000 after acquiring an additional 958 shares during the period. Finally, Envestnet Portfolio Solutions Inc. lifted its holdings in Bruker by 3.3% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,606 shares of the medical research company’s stock valued at $1,278,000 after purchasing an additional 432 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.